drugset / Trial / NCT00613379
PRO 140 by IV Administration in Adults With HIV-1 Infection
Phase 2
Completed
30 enrolled
CytoDyn, Inc.
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is: 1. To assess and characterize the PK and PD of PRO 140 administered IV 2. To assess the antiviral activity of PRO 140 3. To assess the safety and tolerability of PRO 140
Timeline
- Start
- 2007-12
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leronlimab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Leronlimab | Monoclonal antibody | 10 mg/kg | Intravenous |